Cardiovascular Health Advanced

Extends the basic cardiovascular panel with non-HDL cholesterol and lipoprotein(a). Lipoprotein(a) is a genetically determined cardiovascular risk factor that affects roughly 1 in 5 people and is rarely included in standard lipid panels. Elevated Lp(a) is one of the strongest independent predictors of heart attack and stroke.

This advanced panel builds on the basic cardiovascular screen by adding two markers that significantly enhance risk stratification: non-HDL cholesterol and lipoprotein(a). These additions transform the panel from a standard risk assessment into one that captures genetic and residual cardiovascular risk — the type of risk that persists even when LDL cholesterol is well controlled. Non-HDL cholesterol captures all atherogenic lipoprotein particles, not just LDL. It includes VLDL, IDL, and remnant particles that contribute to plaque formation but are invisible on a standard lipid panel. Many cardiologists now consider non-HDL cholesterol a superior predictor of cardiovascular events compared to LDL alone, particularly in patients with elevated triglycerides where LDL calculations become less accurate. Lipoprotein(a), or Lp(a), is a genetically determined cardiovascular risk factor that affects approximately 20% of the global population. Unlike LDL, Lp(a) levels are largely set by genetics and do not respond significantly to diet or standard statin therapy. Elevated Lp(a) is one of the strongest independent predictors of heart attack, stroke, and aortic valve disease. Importantly, Lp(a) only needs to be tested once in a lifetime since levels remain relatively stable — but it is rarely included in standard pathology orders, meaning many people with high Lp(a) are unaware of their elevated risk. For anyone serious about understanding their cardiovascular risk profile — particularly those with a family history of early heart disease or stroke — this advanced panel provides information that standard lipid testing simply cannot offer.